TAK-063 Placebo

DRUG2 trials

Sponsors

Takeda

Conditions

Ketamine-Induced Brain Activity ChangesPsychotic-like SymptomsSchizophrenia

Phase 1

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

CompletedNCT01879722

TakedaSchizophrenia

Start: 2013-06-01End: 2014-06-01Updated: 2026-05-08

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

CompletedNCT01892189

TakedaKetamine-Induced Brain Activity Changes, Psychotic-like Symptoms

Start: 2013-08-01End: 2014-08-01Updated: 2026-05-08

Related Papers

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.

2017-12-0113 citations